TC
RNAM

TwinBeech Capital’s Avidity Biosciences RNAM Stock Holding History

TwinBeech Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,345
Closed -$563K – 931
2024
Q4 		$563K Buy
+19,345
New +$808K 0.01% 436
2023
Q3 		– Sell
-49,323
Closed -$547K – 859
2023
Q2 		$547K Sell
49,323
-50,263
-50% -$630K 0.01% 504
2023
Q1 		$1.53M Buy
+99,586
New +$2.19M 0.03% 406

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TwinBeech Capital's RNAM Position: Q1 2025 in Review

TwinBeech Capital sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 19,345 shares — an estimated $563K sold.

TwinBeech Capital first reported a position in RNAM in Q1 2023 and held it in 3 quarters. The position peaked at $1.53M in Q1 2023. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • TwinBeech Capital reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • TwinBeech Capital sold 19,345 Avidity Biosciences shares in Q1 2025, an estimated $563K.
  • TwinBeech Capital first reported a position in Avidity Biosciences in Q1 2023 and held it in 3 quarters.
  • TwinBeech Capital's Avidity Biosciences position peaked at $1.53M in Q1 2023.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on TwinBeech Capital's 13F filing for Q1 2025, filed 15 May 2025.